Arizona Newborn Diagnosed with Preventable Syphilis Amid Bicillin L-A Shortage
A newborn in Gila County, Arizona, was diagnosed with preventable congenital syphilis after a critical medication, Bicillin L-A, failed to arrive in time. The pregnant mother was diagnosed with syphilis in late March and required urgent treatment, but delays occurred despite an emergency request submitted to Pfizer, the sole supplier of the U.S.-approved drug. This incident highlights challenges posed by a national shortage of Bicillin L-A, which has been ongoing since July 2025, and questions around the effectiveness of emergency drug access programs.
A newborn in Gila County, Arizona, was diagnosed with preventable congenital syphilis after a pregnant mother's emergency request for essential medication faced significant delays. In late March, the woman was diagnosed with syphilis, prompting an urgent need for treatment. Untreated maternal syphilis can lead to severe complications for infants, including miscarriage, stillbirth, infant death, bone deformities, brain damage, blindness, and deafness.
The required treatment was an injectable form of penicillin, Bicillin L-A, which is the only medication approved in the United States for treating syphilis during pregnancy. However, the nation has experienced a shortage of Bicillin L-A since July 2025. Pfizer, the sole distributor of the drug, maintains an emergency request system for patients at risk of congenital syphilis.
On Friday, March 27, public health officials in Gila County submitted an emergency request through Pfizer's system. Pfizer confirmed receipt the following Monday. Despite this, the medication had not arrived by April 7. An official from the National Coalition of STD Directors intervened, contacting a Pfizer representative to expedite the delivery. The Pfizer representative inquired if a medical request form had been submitted, stating it could not be located by Customer Service.
An official at the Arizona Department of Health Services responded, confirming the county had completed the medical request form but added that the mother had already delivered, effectively missing the critical window to prevent congenital syphilis. This outcome was precisely what health officials had aimed to avoid.
In February, the National Coalition of STD Directors had proposed that Pfizer donate a portion of its Bicillin L-A reserves to state health departments to serve as an immediate backstop for such emergencies. As of early June, Pfizer was still evaluating this proposal, nearly four months after it was initially suggested.
According to STAT News, this Arizona case underscores the ongoing challenges posed by drug shortages and procedural hurdles in public health.
